



Vision

Global adoption of ISBT 128 for all medical products of human origin.



Mission

Enhancing patient safety by promoting and managing the ISBT 128 international information standard for use with medical products of human origin.





- To manage international information standards for transfusion medicine, transplantation, and other applications of medical products of human origin in support of traceability, biovigilance, and patient safety.
- To liaise with health authorities, regulators, scientific and professional societies, user communities, and vendors on standardization in terminology and information technology.
- To provide educational programs which promote the value of, and need for, information standards and policies to support traceability and biovigilence.
- To provide technical consultation regarding the implementation and management of ISBT 128.
- To lead in the continued development of common data structures for information technology, data processing, exchange and transfer, and labeling for medical products of human origin.

ICCBBA Board Members

ICCBBA is governed by a volunteer Board of Directors comprised of leading experts in blood transfusion, cellular therapy, and tissue transplantation from around the world. Board positions are advertised publicly and Board Members typically serve two triennial terms.



W John Armitage United Kingdom



Matthew Kuehnert United States



Mahrukh Getshen Bhutan



CHAIR:
Diane Wilson
United States



VICE CHAIR:
Timothy L Pruitt
United States



SECRETARY: Martin Hildebrandt Germany



TREASURER:
Zbigniew M Szczepiorkowski
United States



Kelly Tilleman Belgium



Ineke Slaper-Cortenbach Netherlands



Joy Mammen India

THANK YOU and farewell to departing Board Members:



Jeremy Chapman Australia




Salwa Hindawi Saudi Arabia

The governance role of the Board ensures that ICCBBA is managed in an effective and efficient manner and is appropriately staffed and funded whilst at the same time ensuring a fee structure that is fair and appropriate. As Board Members receive no remuneration, and have no long term association with ICCBBA they can maintain the necessary balance and independence to ensure stakeholders receive good value for money.

In this way, the ICCBBA Board of Directors has ensured that ICCBBA has developed in a sustainable and responsible manner since its creation in 1994, and will continue to ensure effective controls and efficiencies as ISBT 128 moves forward as the International Standard for Medical Products of Human Origin.


Balance Sheet - US Dollars

Assets				
Current Assets				
Cash	794,085			
Investments	2,925,288			
Total Current Assets		3,719,373		
Equipment				
Office Furniture and Equipment	58,850			
Computer Hardware and Software	67,608			
Less Accumulated Depreciation	(-106,327)			
Net Equipment		20,131		
Deposits		6,254		
Total Assets			3,745,758	



Operating Income - US Dollars

Revenues and Expenses		
Revenue		
Registration and License Fees	1,776,518	
Total Expenses	1,642,695	
Income		
Net Income from Operations	133,823	
Investment Income	269,902	
Net Assets without Donor Restrictions		
Change in Net Assets	403,725	
Beginning of Year	3,308,240	
End of Year	3,711,965	



Total Expenses		
Staff Costs	1,098,865	
Scientific Congresses and Exhibitions	15,662	
Office Rental	92,849	
Professional Services	65,712	
Insurance	22,111	
Bank and Credit Card Fees	29,685	
Donations	60,000	
Depreciation	8,092	
Staff Administrative Travel	6,112	
Office Expenses	36,176	
Communication Services	9,136	
Total	1,642,695	



PO Box 11309 San Bernadino, CA 92423-1309 United States of America

Fax: 1 909 793-6214 Phone: 1 909 793-6516 Email: support@isbt128.org

Annual Report 2020 www.isbt128.org